• Psyched Wellness has contracted the National Research Council of Canada
  • The NRC of Canada was hired to provide expertise in biomedical nanotechnology
  • Work will further preliminary findings indicating anti-inflammatory and antioxidant properties and the study of potential neuroprotective roles of the AME-1 extract
  • Psyched Wellness is a life sciences company focused on the production and distribution of artisanal functional and psychedelic mushrooms
  • Psyched Wellness is up 2.08 per cent, trading at C$0.24 at 12:24 pm ET

Psyched Wellness has contracted the National Research Council of Canada (NRC).

The contract is divided into three objectives over a two-year period.

Work will further preliminary findings indicating anti-inflammatory and antioxidant properties in addition to the study of potential neuroprotective roles of the AME-1 extract.

Psyched Wellness is a life sciences company focused on the production and distribution of artisanal functional and psychedelic mushrooms.

The National Research Council of Canada pecializes in providing vital scientific and technological services to the research and industrial communities of Canada.

The NRC was hired to provide expertise in biomedical nanotechnology.

All the results of the research will belong to Psyched, and the research council does not endorse the findings or Psyched products.

“This investigative study will reveal key nutritional systematic and functional properties of the AME-1 extract. The Amanita Muscaria mushroom functional properties will be further investigated and identified in this scientific approach using modern scientific methods to help understand the functional neuroprotective and immune properties of AME-1,” said Psyched Wellness scientific advisor Brian Tancowny.

Psyched Wellness is a health supplements company dedicated to the distribution of mushroom-derived products and associated consumer packaged goods. The company’s objective is to create premium mushroom-derived products that have the potential to become a leading North American brand in the emerging functional food category.

Psyched Wellness is up 2.08 per cent, trading at C$0.24 at 12:24 pm ET.

More From The Market Online

Psychedelic stock begins take-home LSD microdosing clinical trial

MindBio Therapeutics (CSE:MBIO) secures approvals for MB22001 – a form of LSD – microdosing use by patients in a controlled clinical trial.

Red Light Holland begins experimental research on psilocybin truffles

Red Light Holland has revealed that it has officially begun an experimental research project on its psilocybin truffles.
MindBio Therapeutics chief executive officer Justin Hanka.

Psychedelic stock clears hurdle to treating depression with LSD

Psychedelic stock MindBio (CSE:MBIO) is revealing positive top-line data from its pioneering microdosing clinical trial to treat depression.

Clearmind Medicine to begin alcohol use disorder clinical trial

Clearmind Medicine (CSE:CMND) has received approval to begin its phase I/IIa clinical trial for alcohol use disorder in Israel.